ACVR2B and Skeletal muscle atrophy: Nevertheless, an adequate intake of nutrients should be a prerequisite of any treatment in order to maintain or gain muscle mass.54 In a recent study, Hulmi and coworkers proposed blocking of activin receptor type IIb (ACVR2B) ligands by administration of soluble ligand binding domain of ACVR2B (sACVR2B‐Fc) to counteract doxorubicin‐induced skeletal muscle atrophy.